Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Background Alzheimer's disease (AD) is a complex multifactorial neurodegenerative
disorder and the most common form of dementia. AD is highly heritable, with heritability …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …

Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …